Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQKR
$2585.00
+85.00 (+3.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-12.3B · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$38.8B
P/E
N/A
•EV/EBITDA
11.5x
↓ROE
-0.8%
↓Gross Margin
51.8%
↑Debt/Equity
0.63
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.3%
FCF CAGR
—
FCF margin
2.0%
FCF / Net income
-6.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $201.20B · net income $-605.3M · FCF $4.03B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $201.20B | $201.20B | $190.44B | $187.15B | $167.74B |
| Net Income | $-605.3M | $-605.3M | $-5.36B | $3.06B | $8.03B |
| EBITDA | $6.00B | $6.00B | $2.55B | $9.83B | $12.47B |
| EPS | -40.00 | -40.00 | -357.00 | 104.00 | 532.00 |
| Gross Margin | 51.8% | 51.8% | 52.4% | 58.9% | 63.7% |
| Operating Margin | 0.5% | 0.5% | -2.7% | 1.6% | 5.9% |
| Net Margin | -0.3% | -0.3% | -2.8% | 1.6% | 4.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.63 | 0.63 | 0.63 | 0.52 | 0.35 |
| Current Ratio | 1.09 | 1.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.03B | $4.03B | $-12.26B | $-16.37B | $-16.90B |
| Returns | |||||
| ROE | -0.8% | -0.8% | -6.7% | 3.4% | 9.1% |
| Valuation | |||||
| P/E | — | — | — | 55.87 | 12.29 |
| EV/EBITDA | 11.48 | 11.48 | 34.90 | 12.72 | 8.54 |
| P/B | 0.50 | 0.50 | 0.68 | 1.10 | 1.12 |
| Growth & Yield | |||||
| Revenue Growth | 5.7% | 5.7% | 1.8% | 11.6% | — |
| EPS Growth | 88.8% | 88.8% | -443.3% | -80.5% | — |
| Dividend Yield | 2.9% | 2.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-357.00 → -40.00
Residual
-39.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.